Document:

Exhibit 10.2

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT is made and
entered into this February 6, 2012 by and between Kiwa Bio-tech Products Group Corp., a Delaware corporation having its
principal place of business at 310 N. Indian Hill Blvd., #702 Claremont, California and Steven Ning Ma, an individual, whose address
is Room 402, 36 Lane 380, Tianyaoqiao Road 200030 Shanghai, P. R. of China, (“Executive”), with reference to the following
facts:

RECITALS

WHEREAS, Company is primarily engaged
in the business of developing, manufacturing, distributing and marketing innovative, cost-effective and environmentally safe bio-technological
products for the agricultural, stockbreeding, natural resources and environmental protection markets, primarily in China; and

WHEREAS, Company desires to employ Executive
and to ensure the continued availability to Company of Executive’s services, and Executive desires to accept such employment
from Company and render such services, all in accordance with and subject to the terms and conditions herein set forth;

NOW, THEREFORE, in consideration of
the promises and of the mutual covenants contained herein, and for other good and valuable consideration, receipt of which is hereby
acknowledged, Company and Executive do hereby agree as follows:

AGREEMENT

1. Term of Employment.

1.01. Specified Term. Company
employs Executive, and Executive accepts employment with Company, for a period of 3 years beginning on January 1, 2012, and ending
on December 31, 2014.

1.02. Earlier Termination. This
Agreement may be terminated earlier as hereinafter provided.

1.03. Continuing Effect. Notwithstanding
any termination of this Agreement except for termination under Section 9.02, at the end of the Term or otherwise, the provisions
of Sections 10 and 11 shall remain in full force and effect and the provisions of Section 11 shall be binding upon the legal representatives,
successors and assigns of the Executive.

2. Duties and Obligations
of Executive.

2.01. Title and Description of Duties.
Executive shall serve as the Chief Financial Officer and Chief Operating Officer of Kiwa Bio-tech Products Group, Corp. In that
capacity, Executive shall do and perform all services, acts, or things necessary or advisable to fulfill the duties of a Chief
Financial Officer and Chief Operating Officer. However, Executive shall at all times be subject to the direction of the Chief Executive
Officer (“CEO”), and to the policies established by the Company’s Board of Directors.

    	 

    	 

    

2.02. Loyal and Conscientious Performance
of Duties. Executive agrees that to the best of his ability and experience he will at all times loyally and conscientiously
perform all of the duties and obligations required of him either expressly or implicitly by the terms of this Agreement.

2.03. Devotion of Entire Time to
Company’s Business.

(a) Executive shall
devote his entire productive time, ability, and attention to the business of Company during the term of this Agreement.

(b) During the term
of this Agreement, Executive shall not engage in any other business duties or pursuits whatsoever. Furthermore, during the term
of this Agreement, Executive shall not, whether directly or indirectly, render any services of a commercial, or professional nature
to any other person or organization, whether for compensation or otherwise, without the prior written consent of Company’s
President. However, the expenditure of reasonable amounts of time for educational, charitable, or professional activities shall
not be deemed a breach of this Agreement if those activities do not materially interfere with the services required under this
Agreement.

(c) This Agreement
shall not be interpreted to prohibit Executive from making passive personal investments or conducting private business affairs
if those activities do not materially interfere with the services required under this Agreement. However, Executive shall not,
directly or indirectly, acquire, hold, or retain any interest in any business competing with or similar in nature to the business
of Company.

2.04. Location of Office. Executive’s
principal business office shall be at Company’s corporate headquarters and representative office in Beijing. However, Executive’s
job responsibilities shall include all business travel necessary to the performance of his job.

2.05. Uniqueness of Executive’s
Services. Executive represents and agrees that the services to be performed under the terms of this Agreement are of a special,
unique, unusual, extraordinary, and intellectual character that gives them a peculiar value, the loss of which cannot be reasonably
or adequately compensated in damages in an action at law. Executive therefore expressly agrees that Company, in addition to any
other rights or remedies that Company may possess, shall be entitled to injunctive and other equitable relief to prevent or remedy
a breach of this Agreement by Executive.

2.06. Indemnification for Negligence
or Misconduct. Executive shall indemnify and hold Company harmless from all liability for loss, damage, or injury to persons
or property resulting from the negligence or misconduct of Executive.

2.07. Adherence to Inside Information
Policies. Executive acknowledges that Company is publicly-held and, as a result, has implemented inside information policies
designed to preclude its executives and those of its subsidiaries from violating federal securities laws by trading on material,
non-public information or passing such information on to others in breach of any duty owed to Company its parent or any third party.
Executive shall promptly execute any agreements generally distributed by Company to its employees requiring such employees to abide
by its inside information policies.

    	-2-

    	 

    

3. Obligations of Company.

3.01. General Description. Company
shall provide Executive with the compensation, incentives, benefits, and business expense reimbursement specified elsewhere in
this Agreement.

3.02. Indemnification of Losses of
Executive. Company shall indemnify Executive for all necessary expenditures or losses incurred by Executive in direct consequence
of the discharge of his duties on Company's behalf.

4. Executive Representations.
Executive represents and warrants that:

(a) Executive has the right to enter
into this Agreement and is not subject to any Agreement, commitment, agreement, arrangement or restriction of any kind which would
prevent Executive from performing Executive’s duties and obligations hereunder; and

(b) Executive is
currently in good health and to the best of Executive’s knowledge, Executive is not subject to any undisclosed medical condition
which might have a material effect on Executive’s ability to perform satisfactorily Executive’s services hereunder.

5. Compensation of Executive.

5.01. Annual Salary.

(a) As compensation
for the services to be rendered by Executive hereunder, Company shall pay Executive an annual salary at the rate per annum of $70,000.

(b) Executive shall
receive such annual increases in salary as may be determined by Company’s CEO in his sole discretion at least annually on
or about each anniversary of the execution of this Agreement.

(c) Executive shall
pay the due individual income tax levied by the applicable laws and other individual tax (if applicable) levied for the above benefits
paid by Executives. Company shall be entitled to deduct from each salary payment, all deductions as may be required by applicable
laws, including, without limitation, deductions for U.S.A. federal, state and local income taxes and FICA, and deductions for P.R.C.
applicable laws.

5.02. Salary Continuation During
Disability. If Executive for any reason whatsoever becomes permanently disabled so that he is unable to perform the duties
prescribed herein, Company agrees to pay Executive his monthly installments of salary, payable in the same manner as provided for
the payment of salary herein, for a period of up to six (6) months from the date of disability or until the expiration of the employment
term provided for herein, whichever occurs sooner.

5.03. Repayment of Disallowed Salary.
In the event that any portion of the compensation paid by Company to Executive is disallowed as an income tax deduction on an income
tax return of Company, Executive agrees to immediately repay to Company the full amount of that portion.

    	-3-

    	 

    

6. Executive Incentives

6.01. Cash Bonus Based on Profitability.
At the beginning of any fiscal year during the employment term as herein provided, Company’s CEO shall set forth for Executive
goals and objectives to be accomplished by Executive during that year. For the successful completion of all goals and objectives
by the end of that year, Executive shall receive a performance bonus for his services in addition to any other compensation which
he is entitled to receive hereunder. The amount and form of bonus shall be determined by the CEO and approved by the Board of Directors.
This bonus shall be paid within one month after the meeting of the Board of Directors held in connection with the Company’s
annual meeting of stockholders.

6.02. Stock Incentive Plan.

(a) As additional
compensation, Company agrees to grant Executive each year a number of stock options pursuant to Company’s Stock Incentive
Plan in accordance with the board resolutions regarding stock option allocation plan for each fiscal year.

(c) All terms and
conditions of the Company’s Stock Incentive Plan, including but not limited to option grant, exercise and any other items,
are applicable to Executive as a plan participant.

7. Executive Benefits.

7.01. Annual Vacation. Executive
shall be entitled to two (2) weeks of vacation each year with full pay. Executive may be absent from his employment for vacation
only at such times as Company’s CEO shall determine from time to time. If Executive is unable for any reason to take the
total amount of authorized vacation time during any year, he may accrue that time and add it to vacation time for any following
year or may receive a cash payment in an amount equal to the amount of annual salary attributable to that period.

7.02. Illness. Executive shall
be entitled to five (5) days per year as sick leave with full pay. Sick leave may not be accumulated or accrued for any following
year.

7.03. Employee Benefit Programs.
Executive is entitled to participate in any pension, 401(k), insurance or other employee benefit plan that is maintained by Company
for its executive officers, including programs of life and medical insurance and reimbursement of membership fees in civic, social
and professional organizations

7.04. Insurance. Company shall
provide to Executive and pay premiums on Company's group medical insurance policy offered through Company, covering Executive and
Executive's dependents.

7.05. Severance Package. If Executive's
employment with Company is terminated pursuant to Sections 9.03 or 9.04, Executive shall be entitled to a three (3) month severance
package consisting of Executive's compensation and all benefits as provided for in Sections 5, 6 and 7 and all Executive's remaining
unvested options shall vest immediately. Payments shall be made monthly or in a lump sum payment at the Board's sole discretion.
In the event severance is paid in a lump sum, the cash amount excluding insurance benefits shall be paid at the present value for
the time remaining in the 3-month severance agreement based on the current prime interest rate as charged by the Federal Reserve
Bank in New York.

    	-4-

    	 

    

8. Business Expenses.

8.01. Business Expenses.

(a) Company shall
promptly reimburse Executive for all reasonable business expenses incurred by Executive in promoting the business of Company, including
expenditures for entertainment, gifts, and travel.

(b) Each such expenditure
shall be reimbursable only if it is of a nature qualifying it as a proper deduction on the federal and state income tax return
of Company.

(c) Each such expenditure
shall be reimbursable only if Executive furnishes to Company adequate records and other documentary evidence required by federal
and state statutes and regulations issued by the appropriate taxing authorities for the substantiation of that expenditure as an
income tax deduction.

8.02. Repayment by Executive of Disallowed
Business Expenses. In the event that any expenses paid for Executive or any reimbursement of expenses paid to Executive shall,
on audit or other examination of Company's income tax returns, be determined not to be allowable deductions from Company's gross
income, and in the further event that any such determination is acceded to by the Company or made final by the appropriate federal
or state taxing authority or a final judgment of a court of competent jurisdiction, and no appeal is taken from the judgment or
the applicable period for filing notice of appeal has expired, Executive shall repay to Company the amount of the disallowed expenses.

9. Termination of Employment.

9.01. Death or Disability. Except
as otherwise provided herein, this Agreement shall automatically terminate without act by any party upon the death or disability
of Executive. For purposes of this Section 9.01, "disability" shall mean that for a period of 6 consecutive months, Executive
is incapable of substantially fulfilling the duties set forth in Section 2 because of physical, mental or emotional incapacity
resulting from injury, sickness or disease. In the event of the death of Executive, Executive's estate shall receive any unpaid,
earned compensation due Executive and this Agreement shall terminate. In the event of Executive's disability, the Executive will
be paid compensation, benefits and bonus which may accrue during the period of disability as set forth in Sections 5, 6 and 7.

    	-5-

    	 

    

9.02. Termination for Cause.
Company may terminate Executive's employment pursuant to the terms of this Agreement at any time for cause by giving written notice
of termination. Such termination will become effective upon the giving of such notice. Upon any such termination for cause, Executive
shall have no right to compensation, bonus or reimbursement under Section 5, 6 or 8, or to participate in any employee benefit
programs under Section 7, including the severance package provided for in Section 7.05, except as provided by law, for any subsequent
to the effective date of termination. For purposes of this Section 9.02, "cause" shall mean: (i) Executive is convicted
of a felony which is directly related to Executive's employment or the business of Company or could otherwise reasonably be expected
to have a material adverse effect on Company's business, prospects or future stock price which price should be measured over a
period of at least six months. Felonies involving the driving of motor vehicles shall not be grounds for termination; (ii) Executive,
in carrying out his duties hereunder, has been found in a civil action to have committed gross negligence or intentional misconduct
resulting in either case in direct material harm to Company; (iii) Executive is found in a civil action to have breached his fiduciary
duty to Company resulting in direct profit to him; (iv) Executive is found in a civil action to have materially breached any provision
of Section 10 or Section 11; (v) Executive’s repeated refusal (other than any failure to perform arising from a physical
or mental disability) to act in accordance with the reasonable directions of Company’s Board directing Executive to perform
services consistent with Executive’s status as an officer of Company, which refusal is not cured by Executive within twenty
(20) days of Executive’s receipt of written notice thereof from Company (provided, however, that if such breach cannot be
cured within twenty (20) days and Executive commences the cure thereof and diligently pursues the same, such failure shall not
constitute “cause” unless such breach is not cured in its entirety within thirty (30) days of Executive’s receipt
of the written notice of breach); (vi) Executive commits acts of dishonesty, fraud, misrepresentation, or other acts of moral turpitude,
that would prevent the effective performance of his duties; and (vii) Executive’s material breach of any obligations of Executive
which remains uncured for more than twenty (20) days after written notice thereof by Company to Executive. Executive's failure
to comply with the requirements of Section 10 of this Agreement shall constitute a material breach of this Agreement. The term
"found in a civil action" shall not apply until all appeals permissible under the applicable rules of procedure or statute
have been determined and no further appeals are permissible.

9.03. Termination Without Cause.
Company's Board, in its sole discretion, may terminate Executive's employment without cause at any time upon thirty (30) days written
notice. Upon effectiveness of such termination, Executive shall be entitled to the severance package provided for in Section 7.05.

9.04. Effect of Merger, Transfer
of Assets, or Dissolution. This Agreement shall be automatically terminated by any voluntary or involuntary dissolution of
Company resulting from either a merger or consolidation in which Company is not the consolidated or surviving corporation, or a
transfer of all or substantially all of the assets of Company.

9.05. Termination by Executive.
Executive may terminate his obligations under this Agreement at any time in which case Executive shall not be entitled to any severance
benefits pursuant to this Agreement..

10. Non-Competition Agreement.

10.01. Competition with Company.
Until termination of his employment and for a period of 12 months commencing on the date of termination, Executive, directly or
indirectly, in association with or as a stockholder, director, officer, consultant, employee, partner, joint venturer, member or
otherwise of or through any person, firm, corporation, partnership, association or other entity, shall not compete with Company
or any of its affiliates in any line of business which is competitive with the business of Company within any metropolitan area
in the United States and the People’s Republic of China; provided, however, the foregoing shall not prevent Executive from
accepting employment with an enterprise engaged in two or more lines of business, one of which is the same or similar to Company's
business (the "Prohibited Business") if Executive's employment is totally unrelated to the Prohibited Business; provided,
further, the foregoing shall not prohibit Executive from owning up to 5% of the securities of any publicly-traded enterprise provided
Executive is not an executive, director, officer, consultant to such enterprise or otherwise reimbursed for services rendered to
such enterprise.

    	-6-

    	 

    

10.02. Solicitation of Customers.
During the periods in which the provisions of Section 10.01 shall be in effect, Executive, directly or indirectly, will not seek
Prohibited Business from any Customer (as defined below) on behalf of any enterprise or business other than Company that is in
direct competition with Company's business, refer Prohibited Business from any Customer to any enterprise or business other than
Company to any enterprise or business that is in direct competition with Company's business or receive commissions based on sales
or otherwise relating to the Prohibited Business from any Customer that is in direct competition with Company's business, or any
enterprise or business other than Company. For purposes of this Agreement, the term "Customer" means any person, firm,
corporation, partnership, association or other entity to which Company or any of its affiliates sold or provided goods or services
during the six-month period prior to the time at which any determination is required to be made as to whether any such person,
firm, corporation, partnership, association or other entity is a Customer, or who or which was approached by or who or which has
approached an employee of Company for the purpose of soliciting business from the Company or the third party, as the case may be.

10.03. No Payment. Executive
acknowledges and agrees that no separate or additional payment to him will be required in consideration of his undertakings in
this Section 10.

11. Non-Disclosure of Confidential
Information.

11.01. Confidential Information.
Confidential Information includes, but is not limited to, trade secrets as defined by the common law and statute in the state of
California or any future Californian statute, processes, policies, procedures, techniques, designs, drawings, know-how, show-how,
technical information, specifications, computer software and source code, information and data relating to the development, research,
testing, costs, marketing, Company's budgets and strategic plans, and the identity and special needs of Customers, databases, data,
all technology relating to Company's businesses, systems, methods of operation, client or Customer lists, Customer information,
solicitation leads, marketing and advertising materials, methods and manuals and forms, all of which pertain to the activities
or operations of Company, names, home addresses and all telephone numbers and e-mail addresses of Company's executives, former
executives, clients and former clients. In addition, Confidential Information also includes Customers and the identity of and telephone
numbers, e-mail addresses and other addresses of executives or agents of Customers (each a "Contact Person") who are
the persons with whom Company's executives and agents communicate in the ordinary course of business. Confidential Information
also includes, without limitation, Confidential Information received from the Company's subsidiaries and affiliates. For purposes
of this Agreement, the following will not constitute Confidential Information (i) information which is or subsequently becomes
generally available to the public through no act of Executive, (ii) information set forth in the written records of Executive prior
to disclosure to Executive by or on behalf of Company which information is given to Company in writing as of or prior to the date
of this Agreement, and (iii) information which is lawfully obtained by Executive in writing from a third party (excluding any affiliates
of Executive) who did not acquire such confidential information or trade secret, directly or indirectly, from Executive or Company.

    	-7-

    	 

    

11.02. Legitimate Business Interests.
Executive recognizes that Company has legitimate business interests to protect and as a consequence, Executive agrees to the restrictions
contained in this Agreement because they further Company's legitimate business interests. These legitimate business interests include,
but are not limited to: (i) trade secrets; (ii) valuable confidential business or professional information that otherwise does
not qualify as trade secrets including all Confidential Information; (iii) substantial relationships with specific prospective
or existing Customers or clients; (iv) Customer or client goodwill associated with Company's business; and (v) specialized training
relating to Company's technology, methods and procedures.

11.03. Confidentiality. For a
period of two (2) years following termination of employment, the Confidential Information shall be held by Executive in the strictest
confidence and shall not, without the prior written consent of Company, be disclosed to any person other than in connection with
Executive's employment by Company. Executive further acknowledges that such Confidential Information as is acquired and used by
Company or its affiliates is a special, valuable and unique asset. Executive shall exercise all due and diligence precautions to
protect the integrity of Company's Confidential Information and to keep it confidential whether it is in written form, on electronic
media or oral. Executive shall not copy any Confidential Information except to the extent necessary to his employment nor remove
any Confidential Information or copies thereof from Company's premises except to the extent necessary to his employment and then
only with the authorization of the CEO of Company. All records, files, materials and other Confidential Information obtained by
Executive in the course of his employment with Company are confidential and proprietary and shall remain the exclusive property
of Company or its Customers, as the case may be. Executive shall not, except in connection with and as required by his performance
of his duties under this Agreement, for any reason use for his own benefit or the benefit of any person or entity with which he
may be associated or disclose any such Confidential Information to any person, firm, corporation, association or other entity for
any reason or purpose whatsoever without the prior written consent of the CEO of Company.

12. Equitable Relief.

(a) Company and Executive recognize
that the services to be rendered under this Agreement by Executive are special, unique and of extraordinary character, and that
in the event of the breach by Executive of the terms and conditions of this Agreement or if Executive, without the prior consent
of the board of directors of Company, shall leave his employment for any reason and take any action in violation of Section 10
or Section 11, Company shall be entitled to institute and prosecute proceedings in any court of competent jurisdiction referred
to in Section 12(b) below, to enjoin Executive from breaching the provisions of Section 10 or Section 11. In such action, Company
shall not be required to plead or prove irreparable harm or lack of an adequate remedy at law or post a bond or any security.

(b)
Any action must be commenced in Los Angeles County, California. Executive and Company irrevocably and unconditionally submit to
the exclusive jurisdiction of such courts and agree to take any and all future action necessary to submit to the jurisdiction
of such courts. Executive and Company irrevocably waive any objection that they now have or hereafter irrevocably waive any objection
that they now have or hereafter may have to the laying of venue of any suit, action or proceeding brought in any such court and
further irrevocably waive any claim that any such suit, action or proceeding brought in any such court has been brought in an
inconvenient forum. Final judgment against Executive or Company in any such suit shall be conclusive and may be enforced in other
jurisdictions by suit on the judgment, a certified or true copy of which shall be conclusive evidence of the fact and the amount
of any liability of Executive or Company therein described, or by appropriate proceedings under any applicable treaty or otherwise.

    	-8-

    	 

    

13. Conflicts of Interest.
While employed by Company, Executive shall not, directly or indirectly:

(a) participate as an individual in
any way in the benefits of transactions with any of Company's Customers, including, without limitation, having a financial interest
in Company's Customers, or making loans to, or receiving loans, from, Company's Customers;

(b) realize a personal
gain or advantage from a transaction in which Company has an interest or use information obtained in connection with Executive's
employment with Company for Executive's personal advantage or gain; or

(c) accept any offer to serve as an
officer, director, partner, consultant, manager with, or to be employed in a technical capacity by, a person or entity which does
business with Company.

14. General Provisions.

14.01. Notices. Notices and Addresses.
All notices, offers, acceptance and any other acts under this Agreement (except payment) shall be in writing, and shall be sufficiently
given if delivered to the addressees in person, by Federal Express or similar receipted delivery, by facsimile delivery or, if
mailed, postage prepaid, by certified mail, return receipt requested, as follows:

 

	To Company:	Kiwa Bio-Tech Products Group, Corp.
	 	310 N. Indian Hill Blvd., #702
	 	Claremont, California

 

or to such other address as either of
them, by notice to the other may designate from time to time. The transmission confirmation receipt from the sender's facsimile
machine shall be evidence of successful facsimile delivery. Time shall be counted to, or from, as the case may be, the delivery
in person or by mailing

14.02. Attorneys' Fees and Costs.
If any legal action is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to
reasonable attorneys' fees, costs, and necessary disbursements in addition to any other relief to which that party may be entitled.
This provision shall be construed as applicable to the entire Agreement.

14.03. Modifications. Any modification
of this Agreement will be effective only if it is in writing signed by the party to be charged.

14.04. Effect of Waiver. The
failure of either party to insist on strict compliance with any of the terms, covenants, or conditions of this Agreement by the
other party shall not be deemed a waiver of that term, covenant, or condition, nor shall any waiver or relinquishment of any right
or power at any one time or times be deemed a waiver or relinquishment of that right or power for all or any other times.

    	-9-

    	 

    

14.05. Partial Invalidity. If
any provision in this Agreement is held by a court of competent jurisdiction to be invalid, void, or unenforceable, the remaining
provisions shall nevertheless continue in full force without being impaired or invalidated in any way.

14.06. Law Governing Agreement.
This Agreement shall be governed by and construed in accordance with the laws of the State of California.

14.07. Counterparts. This Agreement
may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute
one and the same instrument. The execution of this Agreement may be by actual or facsimile signature.

14.08. Additional Documents.
The parties hereto shall execute such additional instruments as may be reasonably required by their counsel in order to carry out
the purpose and intent of this Agreement and to fulfill the obligations of the parties hereunder.

14.09. Section and Paragraph Headings.
The section and paragraph headings in this Agreement are for reference purposes only and shall not affect the meaning or interpretation
of this Agreement.

14.10. Arbitration. Except for
a claim for equitable relief, any controversy, dispute or claim arising out of or relating to this Agreement, or its interpretation,
application, implementation, breach or enforcement which the parties are unable to resolve by mutual agreement, shall be settled
by submission by either party of the controversy, claim or dispute to binding arbitration in Los Angeles County, California (unless
the parties agree in writing to a different location), before three arbitrators in accordance with the rules of the American Arbitration
Association then in effect. In any such arbitration proceeding the parties agree to provide all discovery deemed necessary by the
arbitrators. The decision and award made by the arbitrators shall be final, binding and conclusive on all parties hereto for all
purposes, and judgment may be entered thereon in any court having jurisdiction thereof.

14.11. Entire Agreement. This
Agreement supersedes any and all other Agreements, either oral or in writing, between the parties hereto with respect to the employment
of Executive by Company, and contains all of the covenants and Agreements between the parties with respect to that employment in
any manner whatsoever. Each party to this Agreement acknowledges that no representations, inducements, promises, or agreements,
orally or otherwise, have been made by any party, or anyone acting on behalf of any party, which are not embodied herein, and that
no other agreement, statement, or promise not contained in this Agreement shall be valid or binding.

[SPACE BELOW INTENTIONALLY
LEFT BLANK]

    	-10-

    	 

    
 

IN WITNESS WHEREOF, Company and Executive have
executed this Agreement as of the date and year first above written.

 

COMPANY:

 

Kiwa Bio-tech Products Group Corp.

 

/s/ Wei Li

Wei Li,

Chairman of Board and CEO

February 6, 2012

 

 

 

EXECUTIVE:

 

/s/ Steven Ning Ma

Steven Ning Ma

February 6, 2012

    	-11-Amendment
No. 5

to

Tranche
A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible Notes 

This Amendment No.
5 to Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible Notes (this “Amendment”)
is entered into effective as of January 31, 2012 (the “Effective Date”), by and among Genesis Biopharma, Inc.,
a Nevada corporation (the “Company”), and the parties set forth on the signature page hereto as the “Holders”
(the “Holders”).

Background

A.The Company
and the Holders are the parties to the (A) Tranche A Senior Unsecured Convertible Notes (the “Tranche A Notes”)
and (B) Tranche B Senior Unsecured Convertible Notes (the “Tranche B Notes”), each as amended by Amendment No.
1 to Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible Notes, dated as of November 30, 2011,
Amendment No. 2 to Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible Notes, dated as of December
19, 2011, Amendment No. 3 to Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible Notes, dated
as of January 5, 2012 and Amendment No. 4 to Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible
Notes, dated as of January 13, 2012.

B.The Holders
own all of the currently outstanding Tranche A Notes and Tranche B Notes.

C.The Company
and the Holders wish to further amend the Tranche A Notes and the Tranche B Notes as set forth in this Amendment.

Agreement

The Company and
the Holders agree as follows:

1.The capitalized
term “Maturity Date” as defined in Section 1 of each of the Tranche A Notes is hereby amended and hereafter shall be
defined to be February 29, 2012.

2.The capitalized
term “Maturity Date” as defined in Section 1 of each of the Tranche B Notes is hereby amended and hereafter shall be
defined to be February 29, 2012.

3.Except as
expressly set forth in the preceding Sections 1 and 2, each of the Tranche A Notes and the Tranche B Notes shall remain in full
force and effect.

4.Each Holder
represents and warrants to the Company that this Amendment has been duly authorized, executed and delivered by him, her or it and
constitutes his, her or its legal, valid and binding obligation, enforceable against him, her or it in accordance with its terms.

    	1

    	 

    
 

5.The Company
represents and warrants to the Holders that this Amendment has been duly authorized, executed and delivered by the Company and
constitutes the Company’s legal, valid and binding obligation, enforceable against the Company in accordance with its terms.

6.This Amendment
may be executed in counterparts, each of which shall constitute an original, but all of which when taken together shall constitute
a single contract.

7.THIS AMENDMENT
SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS AND DECISIONS OF THE STATE OF NEW YORK, WITHOUT REGARD
TO CONFLICT OF LAWS PRINCIPLES WHICH MIGHT CAUSE THE LAWS OF ANY OTHER JURISDICTION TO BE APPLIED.

    	2

    	 

    
 

IN WITNESS WHEREOF,
the Company and the Holders have duly executed this Amendment effective as of the Effective Date.

	COMPANY:	 	HOLDER:
	 	 	 	 	 
	GENESIS BIOPHARMA, INC.	 	Ayer Capital Partners Master Fund, L.P.
	 	 	 	 	 
	 	 	 	 	 
	By:		 	By:		 
	Name:	 	 	Name:	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	HOLDER:	 	HOLDER:
	 	 	 	 	 
	Epworth-Ayer Capital	 	Bristol Investment Fund, Ltd.
	 	 	 	 	 
	 	 	 	 	 
	By:	 	 	By:	 
	Name:	 	 	Name:	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	 	 	 	 	 
	HOLDER:	 	 	 
	 	 	 	 	 
	Ayer Capital Partners Kestrel Fund, LP	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	By:	 	 	 	 
	Name:	 	 	 	 
	Title:	 	 	 	 

 

    	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}]]